OXERVATE eye drops show lasting healing for rare eye disease
NCT ID NCT05552261
First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 28 times
Summary
This study looked at the long-term safety and effectiveness of OXERVATE eye drops in 24 people with stage 1 neurotrophic keratitis, a rare eye condition that can damage the cornea. Participants had already completed the DEFENDO study. Researchers checked if the cornea stayed healed and if eye sensitivity improved up to 30 months after treatment. The goal was to see if the benefits last over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROTROPHIC KERATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cincinnati Eye Institute
Edgewood, Kentucky, 41017, United States
-
New Vision Institute
San Diego, California, 92037, United States
-
Scheie Eye Institute
Philadelphia, Pennsylvania, 19104, United States
-
Tufts Medical Center
Boston, Massachusetts, 02011, United States
Conditions
Explore the condition pages connected to this study.